17 December 2012 -- ZEINCRO, a specialist provider of clinical research services, announces today that it has reinforced its position in Central- and South- Eastern Europe (CSEE), with the opening of offices in 5 additional countries, extending its reach to 14 countries in total.
In addition to its established presence in Cyprus, Greece, Hungary, Romania and Turkey, ZEINCRO now has offices in Bulgaria, Czech Republic, Estonia, FYROM and Poland. With an expanded workforce of more than 200 and over a decade’s operational experience, ZEINCRO is now positioned to offer its global drug development customers clinical trial services in 14 countries – including Latvia, Lithuania, Moldova and Slovakia – that cover the majority of the geographical regions of CSEE and provide access to a population of 250M people.
“Our extensive experience in providing specialist clinical services has taught us that, in order to gain a thorough understanding of a particular community and to forge long-lasting relationships with authorities and healthcare professionals, we need to establish local presence,” commented Prof. Gregory Sivolapenko, Chairman of ZEINCRO. “Our expansion in these additional countries underlines our efforts to set new standards for successful clinical trials and become the leading single provider of clinical research in the CSEE region.”
ZEINCRO delivers bespoke clinical research services that are flexible and ethical, maximising patient recruitment and compliance. In addition to clinical research services, ZEINCRO provides additional services in the areas of post-marketing safety and efficacy studies, regulatory affairs and pharmacovigilance including risk management plans.
About ZEINCRO
ZEINCRO is a leading contract research organisation specialist covering 14 countries in Central- and South-Eastern Europe (Bulgaria, Cyprus, Czech Republic, Estonia, FYROM, Greece, Hungary, Latvia, Lithuania, Moldova, Poland, Romania, Slovakia and Turkey).
With over a decade’s experience in successful clinical research projects in the region, more than 200 ZEINCRO employees have developed a thorough understanding of the communities and the regions in which they operate and have established strong professional links with their local healthcare stakeholders. This approach allows ZEINCRO to set new standards for successful clinical trials by delivering bespoke services that are flexible, ethical and maximise patient recruitment and compliance.
ZEINCRO provides clinical trial services to the global drug development industry and offers additional services in post-marketing safety and efficacy studies, regulatory affairs and pharmacovigilance including risk management plans.
For more information, visit www.zeincro.com
For more information, please contact:
ZEINCRO
Takis Zervakakis, VP Marketing & Business Development
+30 210 8047709
tzervakakis@zeincro.com
For media enquiries, please contact:
College Hill Life Sciences
Lynne Trowbridge, Anastasios Koutsos, Henry Stanley
+44 20 7457 2020
zeincro@collegehill.com
